DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/jj3sz9/investigation) has announced the addition of the "Investigation Report on China's Sodium Ibandronate Market, 2010-2019" report to their offering.
First registered and used in the clinic under the trade name of Bondronat in Germany and Austria in 1996, sodium ibandronate was approved by the FDA to come into the market as a daily treatment of osteoporosis under the trade name of Boniva. However, since drug makers later developed more convenient dose, Boniva has not appeared in the American market until the FDA approved its monthly use in 2005.
The number of new cases of cancer is over 3 million each year in China, among of which about 50% suffer from bone metastasis. In 2001, some local enterprises began to apply for relevant products of sodium ibandronate and succeeded in 2002. In Jul. 2006, sodium ibandronate produced by Roche entered China under the trade name of Bondronat. Since then, sodium ibandronate has developed fast, annual sales value rising from CNY 50.38 million in 2010 to CNY 87.23 million in 2014 and CAGR during this period reaching up to 14.71%. sodium ibandronate enjoys a vast demand in China. Currently, sodium ibandronate market in China is mainly occupied by the following companies: Science & Technology General Company Hebei Medical University, Roche Diagnostics GmbH GE), Hencer Pharmacy and Easton Pharmaceutical Co., Ltd, among which Science & Technology General Company Hebei Medical University has the largest market share of about 58% for sales value in 2014.
With the degradation of environmental pollution and the ageing population, the number of new cases of cancer each year is expected to keep increasing, which shall boost the growth of sodium ibandronate market in China.
Key Topics Covered:
1 Related Concepts of Sodium Ibandronate
2 Market Profile of Sodium Ibandronate in China
3 Survey on Sales Status of Sodium Ibandronate in China, 2010-2014
4 Survey on Market Share of Major Manufacturers of Sodium Ibandronate in China, 2010-2014
5 Survey on Dosage Forms of Sodium Ibandronate in China, 2010-2014
6 Reference Price of Sodium Ibandronate in Chinese Hospitals in 2014
7 Major Manufacturers of Sodium Ibandronate in Chinese Market, 2010-2014
8 Market Outlook of Sodium Ibandronate in China, 2015-2019
- Hencer Pharmacy
- Science & Technology General Company Hebei Medical University
- Roche Diagnostics GmbH
- Easton Pharmaceutical Co., Ltd
For more information visit http://www.researchandmarkets.com/research/jj3sz9/investigation